EW Edwards Lifesciences Corp Insider Trading

CVP Donald E Jr Bobo sells 23,145 EW shares at $86.42; stock near 52-week high; 0 of 5 prior same-ticker sells well-timed.

Donald E Jr Bobo, CVP of Strategy and Corporate Development, sold 23,145 shares at $86.42, reducing holdings by 19.0% to 98,611 shares. The sale occurred near the 52-week high ($87.93), with the current price at $86.51 just 1.6% below peak. Edwards Lifesciences shows solid fundamentals (11.6% annual revenue growth, $380.7M net income on $1.6B quarterly revenue, P/E of 45.53), supporting valuations around these levels. Notably, across his five prior same-ticker trades, 0 of 5 sells showed negative 90-day returns (well-timed indicator for sell activity), suggesting a pattern of selling into strength rather than ahead of declines. While his cross-ticker track record shows a 37.50% well-timed rate on 8 sells, this ticker-specific history of selling at or near peaks without subsequent downside protection offers a less favorable signal for position conviction.

CVP Donald E Jr Bobo sold 17,968 shares at EW for $1,472,678.46 on 2026-05-15; reduces holdings 36.7%.

Donald E Jr Bobo, CVP of Strategy and Corporate Development, executed 2 separate sales totaling 17,968 shares for $1,472,678.46 at a blended average price of $81.96 on 2026-05-15. The transaction represents a -36.7% reduction in his holdings, from 48,937 shares to 30,969 shares post-sale. At the time of the filing, the stock traded at $82.39, within its 52-week range of $72.30–$87.89 and -6.3% from the 52-week high. Edwards Lifesciences reported latest-quarter revenue of $1,648,600,000.00 and net income of $380,700,000.00, with annual revenue growth of +11.6% and a P/E of 43.36. The magnitude and composition of this sale—two distinct transactions executed the same day—warrant attention to the timing and context of his decision relative to the company's fundamentals and his own transaction history.

CEO Bernard Zovighian sells $4.9M in EW shares in multi-transaction filing; 11th open-market sale in 36 months, part of planned equity dispositions.

Bernard Zovighian, Edwards Lifesciences' CEO, executed a significant multi-leg equity transaction disposing of roughly $4.9 million in stock across several sales and gifts over two days in May. This marks his 10th and 11th open-market sales in the past three years—a consistent pattern of selling rather than buying, with only one prior open-market purchase recorded. The stock is trading well below its 52-week high, yet Zovighian chose to sell into this weakness rather than accumulate. His prior five sales at this ticker showed mixed timing results—four were poorly-timed exits where the stock rose afterward, and one was well-timed as shares declined—suggesting his sales have not historically caught major downturns. The company itself remains profitable with growing revenues, trading at a moderate valuation, so the sales do not appear to be driven by fundamental deterioration. The combination of his heavy reliance on equity dispositions over acquisitions, the current sale size relative to his holdings, and the weak price position raises questions about whether this represents ordinary portfolio management or a signal worth deeper investigation.

CFO Ullem Scott B. sold 13,000 shares for $1,040,544.36 under pre-arranged 10b5-1 plan (adopted 2025-07-29).

Ullem Scott B., CVP and Chief Financial Officer of Edwards Lifesciences, executed two separate sales totaling 13,000 shares on 2026-04-09 at prices of $80.50 and $79.79, generating $1,040,544.36. This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-07-29, meaning it was scheduled and not discretionary. Post-transaction, the CFO retained 39,699 shares, representing a 24.7% reduction from pre-transaction holdings of 52,699 shares. As a scheduled disposition under a Rule 10b5-1 plan, this sale reflects pre-established execution rather than a current-moment investment decision by the insider.

CVP Donald Bobo sold 22,680 shares of Edwards Lifesciences at blended average $80.16 under pre-arranged 10b5-1 plan

Donald Bobo, CVP of Strategy and Corporate Development, executed 2 separate sales totaling 22,680 shares for $1,818,055.25 at prices of $80.59 and $80.05 on 2026-04-02. This represents a -51.6% reduction in his holdings, bringing his post-transaction position to 21,266 shares from 43,946 shares. The sales were conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-02-27, indicating these were scheduled, non-discretionary transactions rather than spontaneous market decisions. For investors monitoring insider positioning changes, the material reduction in a senior executive's stake warrants attention to understand whether the divestiture reflects a planned liquidity event or carries broader signaling value.

CFO Ullem Scott B. sold 13,000 shares for $1.1M; 3 of 5 prior EW sales were well-timed at 90-day mark

CFO Ullem Scott B. executed 2 separate sales totaling 13,000 shares for $1,103,895.79 on 2026-03-11, reducing holdings by 24.7% from 52,699 to 39,699 shares. The blended average price of $84.92 is 0.2% below the current price of $85.09, and notably near the 52-week high of $87.18. Examining his prior trade timing at Edwards Lifesciences, 3 of 5 earlier sales showed negative 90-day returns (well-timed sells), suggesting pattern sensitivity to subsequent price declines. However, his cross-ticker track record shows an average 90-day return of -2.9% across 20 prior sells, with a 55.00% well-timed rate—modestly above random. The sale occurs within a context of strong fundamentals: $1.6B quarterly revenue, +11.6% annual growth, and $291.1M net income, though the P/E of 46.24 reflects a valuation premium.

CVP Donald E Bobo Jr sold 24,000 EW shares at $83.84 on 2026-02-25; 90d timing pattern suggests well-timed exit consistent with his prior 3 trades at this ticker.

Donald E Bobo Jr, CVP of Strategy/Corporate Development, executed a substantial sale of 24,000 shares ($2.0M) at $83.84, reducing his holdings from 45.3K to 21.3K shares (-53.0%). His prior 3 trades at Edwards Lifesciences all displayed negative 90-day returns (-8.2%, -0.4%, and -0.4%), meaning he consistently sold before subsequent declines. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 3 prior sells with an average 90d return of -1.6%. The current price of $85.90 represents a 1.2% pullback from the 52-week high of $86.94, placing the company in a stretched valuation context (P/E of 46.68) despite solid fundamentals (revenue growth of +11.6%, $291.1M net income). The confluence of a pattern of well-timed exits at this specific ticker and systematic positive timing across his full trading history suggests a deliberate reduction ahead of potential near-term weakness.

CEO Bernard J Zovighian sold 22,430 shares for $1,719,741.31; holdings down 66.1% to 11,516 shares

CEO Bernard J Zovighian executed 2 separate sales totaling 22,430 shares for $1,719,741.31 on 2026-02-12, reducing his holdings by 66.1% from 33,946 shares to 11,516 shares. The blended average sale price of $76.67 occurred against a backdrop of near-term weakness: the stock is trading at $75.87, down 8.7% over 30 days and 12.1% over 90 days from its 52-week high of $86.94. At the same ticker, Zovighian's prior 5 trades show mixed outcomes: only 1 of 3 prior sells with measurable 90-day returns were well-timed (sold before decline), and his most recent two sales on 2025-12-10 and 2025-12-08 have post-sale returns of +2.0% and -0.4% respectively, suggesting the stock has not retreated sharply following those prior exits. The large reduction in CEO ownership warrants attention given the stock's recent underperformance relative to its 52-week high.

EW CEO Zovighian sells 25,350 shares for $2.2M under pre-arranged 10b5-1 plan; holdings drop 74.7%

Zovighian Bernard J, CEO of Edwards Lifesciences, executed 2 separate sales totaling 25,350 shares for $2,153,373.46 under a pre-arranged 10b5-1 trading plan adopted on 2025-02-28. The sales at $85.21 and $83.45 per share reduced his holdings from 33,946 shares to 8,596 shares, a net reduction of 74.7%. Since the FLAG indicates this is a scheduled, not discretionary transaction under 10b5-1 mechanics, the trade reflects pre-planned portfolio activity rather than a real-time market decision. Investors should note the substantial contraction in the CEO's direct shareholding, though the 10b5-1 framework constrains any inference about current conviction or market timing.

CFO Ullem Scott B. sold 7,700 shares of EW at $84.47 on 2025-12-09 for $650,412.07; stock down -9.4% annually.

Ullem Scott B., Chief Financial Officer, sold 7,700 shares (7.7K shares) at $84.47 on 2025-12-09, reducing his holdings from 47,598 shares to 39,898 shares (a -16.2% reduction). His cross-ticker track record shows 20 prior sells with an average 90-day return of -4.0% and a well-timed rate of 50.00%, indicating mixed execution timing. At EW specifically, his prior 3 measurable same-ticker sells were all positively resolved (90-day returns of +4.7%, +7.0%, and +10.2%), meaning the stock rose after each sale — the opposite of what would constitute well-timed selling. Current stock price of $83.28 is -4.1% from the 52-week high of $86.82, and fundamentals show annual revenue growth of -9.4% against a P/E of 35.29 and market cap of $48,327,384,000.00. The transaction itself appears routine and discretionary (no 10b5-1 flag noted), but the juxtaposition of prior poorly-timed same-ticker sales against persistent revenue headwinds warrants tracking.